Orforglipron (LY-3502970) is an oral, non-peptide, small molecule glucagon-like peptide-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company.

[1][2] It is easier to produce than current peptide GLP-1 agonists and is expected to be cheaper.

[3]